FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns a pharmaceutical composition for treating solid cancer or inhibiting cancer cell containing CD43 antibody (differentiation cluster 43) or its antigen-binding fragment, wherein said CD43 antibody or antigen-binding fragment thereof contains CDR1H with SEQ ID NO: 110, CDR2H with SEQ ID NO: 113, CDR3H with SEQ ID NO: 118, CDR1L with SEQ ID NO: 119, CDR2L with SEQ ID NO: 120 and CDR3L with SEQ ID NO: 125, wherein said antibody or its antigen-binding fragment binds to an epitope consisting of 6-9 consecutive amino acids in the amino acid sequence SEQ ID NO: 134, and where said 6–9 consecutive amino acids contain the amino acid sequence SEQ ID NO: 131. Group of inventions also relates to a method for screening an agent for treating solid cancer or inhibiting cancerous stem cell; nucleic acid molecules encoding said CD43 antibody or antigen-binding fragment thereof; recombinant vector containing said nucleic acid molecule.
EFFECT: group of inventions provides treating solid cancer or inhibiting cancer stem cell.
24 cl, 20 ex, 46 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
NEW MODULATORS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2627176C2 |
ANTIBODY SPECIFICALLY BINDING WITH MUC1 AND ITS APPLICATION | 2018 |
|
RU2746413C1 |
ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
"ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
ANTIBODIES RECOGNISING EPITOPE ON CD43 AND CEA EXPRESSED ON MALIGNANT CELLS AND METHODS FOR USING THEM | 2008 |
|
RU2528738C2 |
ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
Authors
Dates
2019-07-18—Published
2016-10-12—Filed